Beyond Diagnostic Accuracy: The Clinical Utility of Diagnostic Tests

被引:224
作者
Bossuyt, Patrick M. M. [1 ]
Reitsma, Johannes B. [1 ,2 ]
Linnet, Kristian [3 ]
Moons, Karel G. M. [2 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol Biostat & Bioinformat, NL-1100 DE Amsterdam, Netherlands
[2] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
[3] Univ Copenhagen, Fac Hlth Sci, Dept Forens Med, Sect Forens Chem, Copenhagen, Denmark
关键词
NATRIURETIC PEPTIDE; ACUTE DYSPNEA; INFORMATION; TECHNOLOGY; FRAMEWORK; MARKERS;
D O I
10.1373/clinchem.2012.182576
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Like any other medical technology or intervention, diagnostic tests should be thoroughly evaluated before their introduction into daily practice. Increasingly, decision makers, physicians, and other users of diagnostic tests request more than simple measures of a test's analytical or technical performance and diagnostic accuracy; they would also like to see testing lead to health benefits. In this last article of our series, we introduce the notion of clinical utility, which expresses-preferably in a quantitative form-to what extent diagnostic testing improves health outcomes relative to the current best alternative, which could be some other form of testing or no testing at all. In most cases, diagnostic tests improve patient outcomes by providing information that can be used to identify patients who will benefit from helpful downstream management actions, such as effective treatment in individuals with positive test results and no treatment for those with negative results. We describe how comparative randomized clinical trials can be used to estimate clinical utility. We contrast the definition of clinical utility with that of the personal utility of tests and markers. We show how diagnostic accuracy can be linked to clinical utility through an appropriate definition of the target condition in diagnostic-accuracy studies. (C) 2012 American Association for Clinical Chemistry
引用
收藏
页码:1636 / 1643
页数:8
相关论文
共 26 条
  • [1] Distraction from randomization in diagnostic research
    Biesheuvel, Cornelis J.
    Grobbee, Diederick E.
    Moons, Karel G. M.
    [J]. ANNALS OF EPIDEMIOLOGY, 2006, 16 (07) : 540 - 544
  • [2] Bossuyt Patrick M M, 2009, Med Decis Making, V29, pE30, DOI 10.1177/0272989X09347013
  • [3] Randomised comparisons of medical tests: sometimes invalid, not always efficient
    Bossuyt, PMM
    Lijmer, JG
    Mol, BWJ
    [J]. LANCET, 2000, 356 (9244) : 1844 - 1847
  • [4] Medical and economic long-term effects of B-type natriuretic peptide testing in patients with acute dyspnea
    Breidthardt, Tobias
    Laule, Kirsten
    Strohmeyer, Anne-Henny
    Schindler, Christian
    Meier, Sophie
    Fischer, Michael
    Scholer, Andre
    Noveanu, Markus
    Christ, Michael
    Perruchoud, Andre P.
    Mueller, Christian
    [J]. CLINICAL CHEMISTRY, 2007, 53 (08) : 1415 - 1422
  • [5] Clarke Lauren D, 2006, J Natl Cancer Inst Monogr, P96, DOI 10.1093/jncimonographs/lgj013
  • [6] Evaluating the utility of personal genomic information
    Foster, Morris W.
    Mulvihill, John J.
    Sharp, Richard R.
    [J]. GENETICS IN MEDICINE, 2009, 11 (08) : 570 - 574
  • [7] A Framework for Assessing the Value of Diagnostic Imaging in the Era of Comparative Effectiveness Research
    Gazelle, G. Scott
    Kessler, Larry
    Lee, David W.
    McGinn, Thomas
    Menzin, Joseph
    Neumann, Peter J.
    van Amerongen, Derek
    White, Leigh Ann
    [J]. RADIOLOGY, 2011, 261 (03) : 692 - 698
  • [8] What is the clinical utility of genetic testing?
    Grosse, Scott D.
    Khoury, Muin J.
    [J]. GENETICS IN MEDICINE, 2006, 8 (07) : 448 - 450
  • [9] Colorectal Cancer Screening for Average-Risk North Americans: An Economic Evaluation
    Heitman, Steven J.
    Hilsden, Robert J.
    Au, Flora
    Dowden, Scot
    Manns, Braden J.
    [J]. PLOS MEDICINE, 2010, 7 (11)
  • [10] Hlatky Mark A, 2009, Circulation, V119, P2408, DOI 10.1161/CIRCULATIONAHA.109.192278